Author

Maryam Latarani

The Open UniversityORCID 0000-0002-2104-6054Unclaimed ORCID profile · follow to get notified of new preprints

Biology Disciplines

Click to filter author papers

Cancer Biology· 1 Pharmacology & Toxicology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Assay:bulk RNA-seq· 2 Organism:human· 2 Approach:statistical model· 2 Research Focus:differential expression· 1 Research Focus:drug response / drug discovery· 1

Frequent Co-Authors

Elena JachettiiD· 2 shared Francesco CreaiD· 2 shared Irene FischettiiD· 2 shared Mark EcclestoniD· 2 shared Yuzhuo Z. WangiD· 2 shared Adam R. BrentnalliD· 1 shared Benedetto GrimaldiiD· 1 shared Cheryl A. HawkesiD· 1 shared

Activity by Year

2025-2026 · peak 1/yr

Co-Author Collaboration Network

10 top collaborators · 39 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersCancer Biology

Elena JachettiORCID

Mutual co-authors in cluster

Author profile →

2 papers

Recent·Most cited

Pharmacological targeting of EED is an effective therapeutic strategy in cellular models of incurable neuroendocrine prostate cancer

Kayleigh J. A. Orchard, George Bryant, Maryam Latarani, Isabel R Misir, Satyanarayana M Yerra, Christos N. Velanis, Marta Banchi, Irene Fischetti, Steven L Turnball, Mark Eccleston, Theresa Kathleen Kelly, Edwina Burke, Zoe R. Maylin, Guido Bocci, Jonathan Shamash, , Francesco Crea

This study compares tazemetostat and ORIC-944 in NEPC and PRAD cells, finding ORIC-944 more effective in inducing apoptosis and growth inhibition.

bioRxiv · Feb 25, 2026 · PreprintCancer Biology

EZH2 inhibition enhances the activity of platinum chemotherapy in aggressive variant prostate cancer

Maryam Latarani, Perla Pucci, Mark Eccleston, Massimiliano Manzo, Priyadarsini Gangadharannambiar, Irene Fischetti, Ilaria Alborelli, Vera Mongiardini, Namra Mahmood, Mario Paolo Colombo, Benedetto Grimaldi, Sushilaben H. Rigas, Shusuke Akamatsu, Cheryl A. Hawkes, Yuzhuo Z. Wang, , Francesco Crea

This study shows that EZH2 inhibition enhances platinum chemotherapy effectiveness in aggressive variant prostate cancer by reducing H3K27me3 and modulating DNA repair and apoptosis pathways.

Epigenomics · Jan 29, 2025Peer-reviewedPharmacology & Toxicology